 |
InterPro: IPR017855 SMAD domain-like
Protein matches
|
UniProtKB Matches: 580 proteins |
|
Accession
|
IPR017855 SMAD_dom-like |
Type
|
Domain |
Signatures
|
|
InterPro Relationships
|
|
Parent
|
IPR008984 SMAD/FHA domain
|
|
Children
|
IPR001132 SMAD domain, Dwarfin-type
IPR019471 Interferon regulatory factor-3
|
|
InterPro annotation
|
|
Entry Details in BioMart
|
Abstract
|
This entry represents SMAD (Mothers against decapentaplegic (MAD) homolog) (also called MH2 for MAD homology 2) domains as well as their structural homologues, such as the transactivation domain of interferon regulatory protein 3 (IRF3), both of which have a beta-sandwich structural fold.
SMAD domains are found at the carboxy terminus of MAD related proteins such as Smads. SMAD (Mothers against decapentaplegic (MAD) homolog) domain proteins are found in a range of species from nematodes to humans. These highly conserved proteins contain an N-terminal MH1 domain that contacts DNA, and is separated by a short linker region from the C-terminal MH2 domain, the later showing a striking similarity to FHA domains. SMAD proteins mediate signalling by the TGF-beta/activin/BMP-2/4 cytokines from receptor Ser/Thr protein kinases at the cell surface to the nucleus. SMAD proteins fall into three functional classes: the receptor-regulated SMADs (R-SMADs), including SMAD1, -2, -3, -5, and -8, each of which is involved in a ligand-specific signalling pathway [1]; the comediator SMADs (co-SMADs), including SMAD4, which interact with R-SMADs to participate in signalling [2]; and the inhibitory SMADs (I-SMADs), including SMAD6 and -7, which block the activation of R-SMADs and Co-SMADs, thereby negatively regulating signalling pathways [3].
|
Structural links
|
|
Publications
|
|
1.
|
Wu JW, Hu M, Chai J, Seoane J, Huse M, Li C, Rigotti DJ, Kyin S, Muir TW, Fairman R, Massague J, Shi Y.
Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.
Mol. Cell 8 1277-89 2001
[PubMed: 11779503]
http://dx.doi.org/10.1016/S1097-2765(01)00421-X
|
|
2.
|
Shi Y, Hata A, Lo RS, Massague J, Pavletich NP.
A structural basis for mutational inactivation of the tumour suppressor Smad4.
Nature 388 87-93 1997
[PubMed: 9214508]
http://dx.doi.org/10.1038/40431
|
|
3.
|
Itoh F, Asao H, Sugamura K, Heldin CH, ten Dijke P, Itoh S.
Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads.
EMBO J. 20 4132-42 2001
[PubMed: 11483516]
http://dx.doi.org/10.1093/emboj/20.15.4132
|
Additional Reading
|
|
Chacko BM, Qin BY, Tiwari A, Shi G, Lam S, Hayward LJ, De Caestecker M, Lin K.
Structural basis of heteromeric smad protein assembly in TGF-beta signaling.
Mol. Cell 15 2004 813-23
[PubMed: 15350224]
http://dx.doi.org/10.1016/j.molcel.2004.07.016
|
|
Hiscott J, Lin R.
IRF-3 releases its inhibitions.
Structure 13 2005 1235-6
[PubMed: 16154077]
http://dx.doi.org/10.1016/j.str.2005.08.001
|
|
Wu JW, Krawitz AR, Chai J, Li W, Zhang F, Luo K, Shi Y.
Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling.
Cell 111 2002 357-67
[PubMed: 12419246]
http://dx.doi.org/10.1016/S0092-8674(02)01006-1
|
|
Takahasi K, Suzuki NN, Horiuchi M, Mori M, Suhara W, Okabe Y, Fukuhara Y, Terasawa H, Akira S, Fujita T, Inagaki F.
X-ray crystal structure of IRF-3 and its functional implications.
Nat. Struct. Biol. 10 2003 922-7
[PubMed: 14555995]
http://dx.doi.org/10.1038/nsb1001
|
|
Qin BY, Liu C, Lam SS, Srinath H, Delston R, Correia JJ, Derynck R, Lin K.
Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation.
Nat. Struct. Biol. 10 2003 913-21
[PubMed: 14555996]
http://dx.doi.org/10.1038/nsb1002
|
|
|
InterPro 23.1
|